Delaware/Christiana Care CCOP was originally funded by the NCI in 1987 and has continued to be an exemplary participant since that time. Currently, CALGB, NSABP, ECOG, RTOG, GOG, COG, Wake Forest, URCC and CTSU are utililzed as research bases. ACOS-OG trials have also been accessed although not through the CCOP mechanism. Our extensive catchment area includes all of Delaware and portions of New Jersey, northeastern Maryland and southeastern Pennsylvania (Delaware and Chester counties). Delaware ranks 3rd in the nation for all cancer site disease incidence, Maryland ranks 35th, New Jersey 5th and Pennsylvania 6th (2007 USCS Data). Our research base represents a popluation base in excess of 2 million people with extensive protocol entry potential. Under the leadership of Stephen S.Grubbs, M.D., Principal Investigator and Kandie Dempsey, MS, RN, OCN, Director, CCOP investigators, project coordinators and data managers will continue to participate in cooperative group core committees and leadership positions. Our mission is to continue accruals to both treatment and cancer control studies. In addition, CCHS is commited to having personnel continue to provide significant contributions in leadership roles on cooperative group core committes and as cooperative group protocol study chairs. The overall impact of this grant will be to ensure continuation and stimulate expansion of CCOP activities, including treatment and cancer control research, at Christiana Care Health Services and its affiliates throughout the catchment area.
Our mission statement is to provide the community with coordinated access to cancer related clinical trials in order to reduce cancer incidence, morbidity and mortality while improving quality of life. Participation in the CCOP provides us with the opportunity to work towards our mission.
|Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21|
|Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50|
|Shulman, Lawrence N; Berry, Donald A; Cirrincione, Constance T et al. (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-7|
|Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11|
|Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38|
|Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43|
|Grant, Barbara W; Jung, Sin-Ho; Johnson, Jeffrey L et al. (2013) A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119:3797-804|
|Edelman, Martin J; Hodgson, Lydia; Rosenblatt, Paula Y et al. (2012) CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 7:649-54|
|Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17|
|Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8|
Showing the most recent 10 out of 74 publications